Pfiz­er hits the gas ped­al in the mR­NA flu vac­cine de­vel­op­ment race, ink­ing a $425M in­vest­ment pact with BioN­Tech

The mR­NA spe­cial­ists at BioN­Tech have added an­oth­er deep-pock­et phar­ma gi­ant to the fold.

Pfiz­er has stepped up with a $120 mil­lion cash com­mit­ment — cov­er­ing an an un­cer­tain mix of up­front cash, eq­ui­ty and near-term re­search sup­port — to get the Ger­man biotech to fo­cus its drug plat­form on sea­son­al and pan­dem­ic flu. And there’s an­oth­er $305 mil­lion on the line in po­ten­tial mile­stone pay­outs if they can score mar­ketable prod­ucts.

Con­cep­tu­al­ly, mR­NA is sim­ple. De­vel­op­ers are adapt­ing a nat­ur­al sys­tem that dis­patch­es in­struc­tions en­cod­ed in RNA that trig­gers the pro­duc­tion of ther­a­peu­tic pro­teins. Cre­at­ing a game-chang­ing plat­form tech that can or­ches­trate this process, and the man­u­fac­tur­ing op­er­a­tions need­ed to pro­duce it, is enor­mous­ly com­plex, in­spir­ing bil­lions of dol­lars worth of in­vest­ments in BioN­Tech, Cure­Vac and Mod­er­na from big play­ers like Sanofi, Genen­tech and As­traZeneca.

And now Pfiz­er is jump­ing in, which is push­ing the to­tal in­vest­ed in BioN­tech so far well past the bil­lion-dol­lar mark.


BioN­Tech’s pipeline is con­cen­trat­ed on on­col­o­gy, with can­cer vac­cines part­nered with Genen­tech as a cen­tral fo­cus. And that’s where they see a key ad­van­tage as re­searchers work with Pfiz­er on the flu.

“Some of the un­der­ly­ing mech­a­nisms are the same,” BioN­Tech COO Sean Marett tells me in his lat­est up­date. “We’ve been us­ing some of that syn­er­gy in in­fec­tious dis­eases for awhile….You can tar­get mR­NA so that you get it to the im­mune cells of choice. We re­al­ly do see that with our on­col­o­gy process.”

One of the key ad­van­tages of mR­NA for flu vac­cines is that it can elim­i­nate the oner­ous and rel­a­tive­ly ex­pen­sive egg-based sys­tem used to or­der up huge batch­es of sea­son­al flu vac­cines as the WHO makes its best guess about which vi­ral strains are like­ly to cause the most trou­ble in the midst of flu sea­son. And the same ba­sic mR­NA ap­proach can be adapt­ed from sea­son­al flu for use against sud­den pan­demics.

“Once the back­bone is op­ti­mized for ex­pres­sion in the rel­e­vant set­ting, it’s just a ques­tion of ex­chang­ing anti­gens,” adds Marett. “In our ex­pe­ri­ence with on­col­o­gy vac­cines, it’s re­al­ly quick. You need the se­quence, the trick is that your back­bone is op­ti­mized.”

For any big play­er in vac­cines, it’s the kind of tech­nol­o­gy that could dis­rupt the en­tire vac­cines field — if it works — and this is one area of mR­NA where re­searchers feel they’re on sol­id ground in search­ing for suc­cess. Not en­gag­ing with one of the lead­ers would leave them vul­ner­a­ble to be­ing cut out of the mar­ket.

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Vlad Coric, Biohaven CEO

Vlad Coric charts course for new Bio­haven with neu­ro­science push and Big Phar­ma vets on board

What’s Biohaven without its CGRP portfolio? That’s what CEO Vlad Coric is tasked with deciding as he maps out the new Biohaven post-Pfizer takeover.

Pfizer officially scooped up Biohaven’s CGRP assets on Monday, including blockbuster migraine drug Nurtec and the investigational zavegepant, for $11.6 billion. As a result, Coric spun the broader pipeline into an independent company on Tuesday — with the same R&D team behind Nurtec but about 1,000 fewer staffers and a renewed focus on neuroscience and rare disease.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

In AstraZeneca's latest campaign, wild eosinophils called Phils personify the acting up often seen in uncontrolled asthma

As­traZeneca de­buts an­noy­ing pur­ple ‘Phil’ crea­tures, per­son­i­fied asth­ma eosinophils ‘be­hav­ing bad­ly’

There are some odd-looking purple creatures lurking around the halls of AstraZenca lately. The “Phil” character cutouts are purple, personified eosinophils with big buggy eyes and wide mouths, and they’re a part of AZ’s newest awareness effort to help people understand eosinophilic asthma.

The “Asthma Behaving Badly” characters aren’t only on the walls at AZ to show the new campaign to employees, however. The “Phils” are also showing up online on the campaign website, and in digital and social ads and posts on Facebook and Instagram.

Christophe Bourdon, Leo Pharma CEO

Leo Phar­ma looks 'be­yond the skin' in atopic der­mati­tis aware­ness cam­paign

As Leo Pharma aims to take on heavyweight champ Dupixent in atopic dermatitis, the company is launching “AD Days Around the World,” an awareness campaign documenting real patient stories across Europe.

The project, unveiled on Monday, spotlights four patients: Marjolaine, Laura, Julia and África from France, Italy, Germany and Spain, respectively, in short video clips on the challenges of living with AD, the most common form of eczema.

Ying Huang, Legend CEO

Lentivi­ral vec­tor ramp-up: J&J and Leg­end to in­vest $500M in New Jer­sey man­u­fac­tur­ing to sup­port Carvyk­ti

In response to a question on manufacturing scale at Legend Biotech’s R&D day yesterday, the company’s top exec said its partnership with Johnson & Johnson will be doubling its investment in its New Jersey manufacturing center and will be investing a total of $500 million.

With an eye on their BCMA-directed CAR-T therapy Carvykti (cilta-cel), approved in February as a fifth-line treatment for multiple myeloma, Legend CEO Ying Huang said that the ramp-up in production and the decision to manufacture its own lentiviral vectors — currently in shortage worldwide — means they won’t have to deal with that shortage.

Mar­ket­ingRx roundup: No­var­tis re­cruits NFL coach for Leqvio cam­paign; Pfiz­er pro­motes ‘Sci­ence’ merch on so­cial me­dia

Novartis is turning to a winning coach to talk about Leqvio and the struggles of high cholesterol — including his own. Bruce Arians, the retired NFL head coach of the Arizona Cardinals and Super Bowl-winning Tampa Bay Buccaneers, is partnering with the pharma for its “Coaching Cholesterol” digital, social and public relations effort.

In the campaign, Arians talks about the potential for “great comebacks” in football and heart health. Once nicknamed a “quarterback whisperer,” he is now retired from fulltime coaching (although still a front-office consultant for Tampa Bay), and did a round of media interviews for Novartis, including one with People and Forbes.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Amy West, Novo Nordisk head of US digital innovation and transformation (Illustration: Assistant Editor Kathy Wong for Endpoints News)

Q&A: No­vo Nordisk dig­i­tal in­no­va­tion chief Amy West dis­cuss­es phar­ma pain points and a health­care 'easy but­ton’

Amy West joined Novo Nordisk more than a decade ago to oversee marketing strategies and campaigns for its US diabetes portfolio. However, her career path shifted into digital, and she hasn’t looked back. West went from leading Novo’s first digital health strategy in the US to now heading up digital innovation and transformation.

She’s currently leading the charge at Novo Nordisk to not only go beyond the pill with digital marketing and health tech, but also test, pilot and develop groundbreaking new strategies needed in today’s consumerized healthcare world.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Benjamine Liu, TrialSpark CEO

Paul Hud­son and Tri­alSpark's mu­tu­al de­sire to speed up de­vel­op­ment con­verges in three-year, six-drug goal

A unicorn startup that originally set out to hasten clinical studies for biopharma partners dug further into its revised path of internal drug development by linking arms with Sanofi in a pact that the biotech’s CEO said originated from the top.

TrialSpark and the Big Pharma on Tuesday committed to in-licensing and/or acquiring six Phase II/Phase III drugs within the next three years.

“I’ve known Paul Hudson for a while and we were discussing the opportunity to really re-imagine a lot of different parts of pharma,” TrialSpark CEO Benjamine Liu told Endpoints News, “and one of the things that we discussed was this opportunity to accelerate the development of new medicines in mutual areas of interest.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.